Effects of Immunocompromise and Comorbidities on Pneumococcal Serotypes Causing Invasive Respiratory Infection in Adults: Implications for Vaccine Strategies | Zendy

Manel Luján | Zendy; Joaquín Burgos | Zendy; Miguel Gallego | Zendy; Vicenç Falcó | Zendy; Guadalupe Bermudo | Zendy; Ana María Planes | Zendy; D. Fontanals | Zendy; Maddalena Peghin | Zendy; Eduard Monsó | Zendy; Jordi Rello | Zendy

Open Access

Effects of Immunocompromise and Comorbidities on Pneumococcal Serotypes Causing Invasive Respiratory Infection in Adults: Implications for Vaccine Strategies

Author(s) -

Manel Luján,

Joaquín Burgos,

Miguel Gallego,

Vicenç Falcó,

Guadalupe Bermudo,

Ana María Planes,

D. Fontanals,

Maddalena Peghin,

Eduard Monsó,

Jordi Rello

Publication year - 2013

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cit640

Subject(s) - medicine , serotype , streptococcus pneumoniae , pneumococcal conjugate vaccine , pneumococcal disease , conjugate vaccine , cohort , pneumococcal vaccine , pneumococcal infections , immunology , virology , antibiotics , microbiology and biotechnology , antibody , immunization , biology

The 13-valent pneumococcal conjugate vaccine (PCV13) has recently been approved for use in immunocompromised adults. However, it is unclear whether there is an association between specific underlying conditions and infection by individual serotypes. The objective was to determine the prevalence of serotypes covered by PCV13 in a cohort of patients with invasive pneumococcal disease of respiratory origin and to determine whether there are specific risk factors for each serotype.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research